Li Zhan-Feng, Sun Xin
Department of Pediatric Hematology, Guangzhou Women and Chirdren's Medical Center, Guangzhou 510623, Guangdong Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1356-60. doi: 10.7534/j.issn.1009-2137.2013.05.054.
One of the major obstacle for hematopoietic stem cell transplantation (HSCT) to treat patients with beta-thalassemia is graft rejection (GR). The proportion of donor-derived cells continually declined in mixed chimerism (MC), finally leading to graft failure. Monitoring chimerism after transplant consecutively can early find unstable mixed chimerism and rejection, which provide the basis for donor lymphocyte infusion (DLI); for imminent risk of graft rejection, escalating doses of DLI is a feasible method for converting unstable MC towards stable MC or full donor chimerism. This review focuses on advancement of chimerism monitoring and DLI after HSCT for patients with β-thalassemia major.
造血干细胞移植（HSCT）治疗β地中海贫血患者的主要障碍之一是移植物排斥（GR）。在混合嵌合体（MC）中，供体来源细胞的比例持续下降，最终导致移植物失败。连续监测移植后的嵌合体可以早期发现不稳定的混合嵌合体和排斥反应，为供体淋巴细胞输注（DLI）提供依据；对于即将发生移植物排斥风险的患者，递增剂量的DLI是将不稳定的MC转化为稳定的MC或完全供体嵌合体的可行方法。本综述重点关注重型β地中海贫血患者HSCT后嵌合体监测和DLI的进展。
